[12] Patent
[11] Patent No.:GC0007597  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126082
Date of the Decision to Grant the Patent:16/Apr/2018

[21] Application No.:GC 2013-25538

[22] Filing Date:9/10/2013

[30] Priority:

[33] State [32] Priority date [31] Priority No.
EP
18/10/2012
12188940.6

[72] Inventors:1- Georg Jaeschke،2- Lothar Lindemann،3- Antonio Ricci،4- Daniel Rueher،5- Heinz Stadler،6- Eric Vieira

[73] Owner: F. Hoffmann-La Roche AG, 124 Grenzacherstrasse, CH-4070, Basle, Switzerland

[74] Agent: Kadasa Law Firm

  

 

  

[51]IPC:
Int. Cl.: C07D 413/06 (2006.01)

[56] Cited Documents:

-WO 2013/049255 A1 (UNIV VANDERBILT [US]) 04 April 2013
-US 2009/042855 A1 (CONN P JEFFREY [US] ET AL) 12 February 2009
-WO 2011/051201 A1 (HOFFMANN LA ROCHE [CH]; GREEN LUKE [CH]; GUBA WOLFGANG [DE]; JAESCHKE) 05 May 2011
 
Examiner: PH. Mohammad S. AlMousa

[54] ETHYNYL DERIVATIVES
[57] Abstract: The present invention relates to ethynyl derivatives of formula I wherein Y is N or CH, R1 is fluoro or chloro, R2 is hydrogen or methyl, or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. It has now surprisingly been found that the compounds of general formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of anxiety and pain, depression, Fragile-X syndrom, autism spectrum disorders, Parkinson’s disease, and gastroesophageal reflux disease (GERD).
No. of claims: 10     No. of figures: 1


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.